Journal Article
. 2018 Jul; 78(18):5327-5339.
doi: 10.1158/0008-5472.CAN-18-0892.

Mucosal HPV E6/E7 Peptide Vaccination in Combination with Immune Checkpoint Modulation Induces Regression of HPV+ Oral Cancers

Stephanie Dorta-Estremera 1 Renee L Chin 1 Gloria Sierra 1 Courtney Nicholas 1 Ananta V Yanamandra 1 Sita M K Nookala 1 Guojun Yang 2 Shail Singh 3 Michael A Curran 1 K Jagannadha Sastry 4 
  • PMID: 30054333
  •     52 References
  •     10 citations


High-risk human papillomavirus (HPV)-associated squamous cell carcinomas of the oropharynx (SCCOP) are among the fastest growing cancers. After standard-of-care treatment, however, patients with HPV+ SCCOP have better overall and disease-specific survival than patients with HPV- SCCOP, suggesting the importance of HPV-specific immunity. We reasoned that therapeutic vaccination targeting the HPV-16 E6 and E7 oncogenes could elicit high-affinity, high-frequency tumor antigen-specific T-cell responses, which could then be augmented and shielded from suppression in the tumor microenvironment by immune checkpoint modulation. In this study, we used a preclinical syngeneic mouse model of oral cancer comprised of mouse tonsil-derived epithelial cells stably expressing HPV-16 E6 and E7 genes along with H-ras oncogene (mEER) to identify combinations of vaccination and checkpoint antibodies capable of promoting tumor regression. Intranasal HPV E6/E7 peptide vaccination and single checkpoint antibodies failed to elicit responses in more than half of animals; however, 4-1BB agonist antibody along with either CD40 agonist antibody or CTLA-4 blockade eliminated the majority of established mEER tumors. The combination of intranasal HPV peptide vaccine and α4-1BB and αCTLA-4 antibodies produced curative efficacy and a better safety profile against orally implanted mEER tumors. Correlates of protective immunity included enhanced intratumoral levels of CD8 T cells relative to immunosuppressive regulatory T cells and myeloid-derived suppressor cells. Overall, our results demonstrate combination vaccine-immunotherapy modalities as novel treatment options for HPV+ SCCOP.Significance: Combinations of vaccine and checkpoint modulation are effective and safe treatment options for HPV+ oral cancers. Cancer Res; 78(18); 5327-39. ©2018 AACR.

Cell-specific and context-dependent effects of GITR in cancer, autoimmunity, and infection.
Derek L Clouthier, Tania H Watts.
Cytokine Growth Factor Rev, 2014 Feb 04; 25(2). PMID: 24484736
Anti-tumour necrosis factor agent and liver injury: literature review, recommendations for management.
Roberta Elisa Rossi, Ioanna Parisi, +5 authors, Charles Daniel Murray.
World J Gastroenterol, 2014 Dec 18; 20(46). PMID: 25516646    Free PMC article.
PD-1 blockade induces responses by inhibiting adaptive immune resistance.
Paul C Tumeh, Christina L Harview, +23 authors, Antoni Ribas.
Nature, 2014 Nov 28; 515(7528). PMID: 25428505    Free PMC article.
Highly Cited.
Mucosal imprinting of vaccine-induced CD8⁺ T cells is crucial to inhibit the growth of mucosal tumors.
Federico Sandoval, Magali Terme, +25 authors, Eric Tartour.
Sci Transl Med, 2013 Feb 15; 5(172). PMID: 23408053    Free PMC article.
Highly Cited.
Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine.
Todd Bartkowiak, Shailbala Singh, +6 authors, Michael A Curran.
Proc Natl Acad Sci U S A, 2015 Sep 10; 112(38). PMID: 26351680    Free PMC article.
An adenoviral cancer vaccine co-encoding a tumor associated antigen together with secreted 4-1BBL leads to delayed tumor progression.
Emeline Ragonnaud, Anne-Marie C Andersson, +2 authors, Peter J Holst.
Vaccine, 2016 Mar 24; 34(18). PMID: 27004934
Immune checkpoints and their inhibition in cancer and infectious diseases.
Lydia Dyck, Kingston H G Mills.
Eur J Immunol, 2017 Apr 11; 47(5). PMID: 28393361
Highly Cited. Review.
Isolation of T cells from mouse oral tissues.
Pushpa Pandiyan, Natarajan Bhaskaran, Yifan Zhang, Aaron Weinberg.
Biol Proced Online, 2014 Mar 13; 16(1). PMID: 24612879    Free PMC article.
Oral cavity and oropharyngeal squamous cell carcinoma--an update.
Angela C Chi, Terry A Day, Brad W Neville.
CA Cancer J Clin, 2015 Jul 29; 65(5). PMID: 26215712
Highly Cited. Review.
Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists.
K S Peggs, S A Quezada, J P Allison.
Clin Exp Immunol, 2009 Aug 08; 157(1). PMID: 19659765    Free PMC article.
Phenotype and Tissue Residency of Lymphocytes in the Murine Oral Mucosa.
Joo-Young Park, Hyunsoo Chung, Youngnim Choi, Jung-Hyun Park.
Front Immunol, 2017 Mar 25; 8. PMID: 28337201    Free PMC article.
Epitope spreading contributes to effective immunotherapy in metastatic melanoma patients.
Nicola Hardwick, Benjamin Chain.
Immunotherapy, 2011 Jun 15; 3(6). PMID: 21668310
Location of tumor affects local and distant immune cell type and number.
Jonathan A Hensel, Vinayak Khattar, +3 authors, Selvarangan Ponnazhagan.
Immun Inflamm Dis, 2017 Mar 03; 5(1). PMID: 28250928    Free PMC article.
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.
Gregory L Beatty, Elena G Chiorean, +10 authors, Robert H Vonderheide.
Science, 2011 Mar 26; 331(6024). PMID: 21436454    Free PMC article.
Highly Cited.
Comprehensive genomic characterization of head and neck squamous cell carcinomas.
Cancer Genome Atlas Network.
Nature, 2015 Jan 30; 517(7536). PMID: 25631445    Free PMC article.
Highly Cited.
Intranasal but not intravenous delivery of the adjuvant α-galactosylceramide permits repeated stimulation of natural killer T cells in the lung.
Amy N Courtney, Prakash Thapa, +3 authors, Jagannadha Sastry.
Eur J Immunol, 2011 Aug 06; 41(11). PMID: 21818755    Free PMC article.
Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.
Mark J Selby, John J Engelhardt, +4 authors, Alan J Korman.
Cancer Immunol Res, 2014 Apr 30; 1(1). PMID: 24777248
Highly Cited.
Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors.
Jens Rüter, Scott J Antonia, +2 authors, Robert H Vonderheide.
Cancer Biol Ther, 2010 Sep 22; 10(10). PMID: 20855968    Free PMC article.
The mucosal immune system in the oral cavity-an orchestra of T cell diversity.
Rui-Qing Wu, Dun-Fang Zhang, +2 authors, WanJun Chen.
Int J Oral Sci, 2014 Aug 12; 6(3). PMID: 25105816    Free PMC article.
Tumor-induced CD11b(+) Gr-1(+) myeloid-derived suppressor cells exacerbate immune-mediated hepatitis in mice in a CD40-dependent manner.
Tamar Kapanadze, José Medina-Echeverz, +11 authors, Tim F Greten.
Eur J Immunol, 2015 Jan 24; 45(4). PMID: 25616156    Free PMC article.
Head and neck cancer: from anatomy to biology.
Pinaki Bose, Nigel T Brockton, Joseph C Dort.
Int J Cancer, 2013 Feb 19; 133(9). PMID: 23417723
Targeted agents and immunotherapies: optimizing outcomes in melanoma.
Jason J Luke, Keith T Flaherty, Antoni Ribas, Georgina V Long.
Nat Rev Clin Oncol, 2017 Apr 05; 14(8). PMID: 28374786
Highly Cited. Review.
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.
Michael A Curran, Welby Montalvo, Hideo Yagita, James P Allison.
Proc Natl Acad Sci U S A, 2010 Feb 18; 107(9). PMID: 20160101    Free PMC article.
Highly Cited.
Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.
Daniel E Speiser, Danielle Liénard, +6 authors, Pedro Romero.
J Clin Invest, 2005 Feb 08; 115(3). PMID: 15696196    Free PMC article.
Highly Cited.
Cutaneous adverse effects of the immune checkpoint inhibitors.
Lindsey K Collins, M Shane Chapman, Joi B Carter, Faramarz H Samie.
Curr Probl Cancer, 2017 Feb 14; 41(2). PMID: 28190531
Perspectives for therapeutic HPV vaccine development.
Andrew Yang, Emily Farmer, T C Wu, Chien-Fu Hung.
J Biomed Sci, 2016 Nov 05; 23(1). PMID: 27809842    Free PMC article.
Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein.
Shin-Ichiro Fujii, Kanako Shimizu, +2 authors, Ralph M Steinman.
J Exp Med, 2003 Jul 23; 198(2). PMID: 12874260    Free PMC article.
Highly Cited.
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma.
Jedd D Wolchok, F Stephen Hodi, +9 authors, Alan J Korman.
Ann N Y Acad Sci, 2013 Jun 19; 1291. PMID: 23772560    Free PMC article.
Highly Cited. Review.
PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?
Sylvain Simon, Nathalie Labarriere.
Oncoimmunology, 2018 Jan 04; 7(1). PMID: 29296515    Free PMC article.
Highly Cited. Review.
Human papillomavirus and rising oropharyngeal cancer incidence in the United States.
Anil K Chaturvedi, Eric A Engels, +15 authors, Maura L Gillison.
J Clin Oncol, 2011 Oct 05; 29(32). PMID: 21969503    Free PMC article.
Highly Cited.
Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma.
Ranjana Advani, Andres Forero-Torres, +6 authors, Jonathan G Drachman.
J Clin Oncol, 2009 Jul 29; 27(26). PMID: 19636010
GITR-dependent regulation of 4-1BB expression: implications for T cell memory and anti-4-1BB-induced pathology.
Gloria H Y Lin, Laura M Snell, +2 authors, Tania H Watts.
J Immunol, 2013 Mar 29; 190(9). PMID: 23536631
Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production.
Michael A Curran, Myoungjoo Kim, +2 authors, James P Allison.
PLoS One, 2011 May 12; 6(4). PMID: 21559358    Free PMC article.
Highly Cited.
The role of human papillomavirus 16 E6 in anchorage-independent and invasive growth of mouse tonsil epithelium.
Andrew C Hoover, William C Spanos, +3 authors, John H Lee.
Arch Otolaryngol Head Neck Surg, 2007 May 23; 133(5). PMID: 17515506    Free PMC article.
Clinical experience with α-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection.
Famke L Schneiders, Rik J Scheper, +6 authors, Hans J van der Vliet.
Clin Immunol, 2010 Dec 21; 140(2). PMID: 21169066
Rationale for anti-OX40 cancer immunotherapy.
Sandrine Aspeslagh, Sophie Postel-Vinay, +3 authors, Aurélien Marabelle.
Eur J Cancer, 2015 Dec 10; 52. PMID: 26645943
Highly Cited. Review.
Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity.
Ergun Kocak, Kenneth Lute, +8 authors, Yang Liu.
Cancer Res, 2006 Jul 20; 66(14). PMID: 16849577
AdCD40L immunogene therapy for bladder carcinoma--the first phase I/IIa trial.
Per-Uno Malmström, Angelica S I Loskog, +5 authors, Thomas H Tötterman.
Clin Cancer Res, 2010 May 08; 16(12). PMID: 20448220
Immune checkpoint combinations from mouse to man.
Midan Ai, Michael A Curran.
Cancer Immunol Immunother, 2015 Jan 04; 64(7). PMID: 25555570
Mutations, expression and genomic instability of the H-ras proto-oncogene in squamous cell carcinomas of the head and neck.
H Kiaris, D A Spandidos, +2 authors, J K Field.
Br J Cancer, 1995 Jul 01; 72(1). PMID: 7599040    Free PMC article.
Immune modulation in cancer with antibodies.
David B Page, Michael A Postow, +2 authors, Jedd D Wolchok.
Annu Rev Med, 2013 Nov 06; 65. PMID: 24188664
Highly Cited. Review.
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
Tumor location impacts immune response in mouse models of colon cancer.
Xianda Zhao, Lihua Li, Timothy K Starr, Subbaya Subramanian.
Oncotarget, 2017 Sep 15; 8(33). PMID: 28903381    Free PMC article.
Enhancing T cell therapy by overcoming the immunosuppressive tumor microenvironment.
Ainhoa Arina, Leticia Corrales, Vincenzo Bronte.
Semin Immunol, 2016 Feb 14; 28(1). PMID: 26872631
Preclinical models of HPV+ and HPV- HNSCC in mice: an immune clearance of HPV+ HNSCC.
Robin Williams, Dong Wook Lee, +3 authors, John H Lee.
Head Neck, 2009 Mar 14; 31(7). PMID: 19283850
Activation of 4-1BB on Liver Myeloid Cells Triggers Hepatitis via an Interleukin-27-Dependent Pathway.
Todd Bartkowiak, Ashvin R Jaiswal, +8 authors, Michael A Curran.
Clin Cancer Res, 2018 Jan 06; 24(5). PMID: 29301830    Free PMC article.
Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials.
Sufia Butt Hassan, Jesper Freddie Sørensen, Barbara Nicola Olsen, Anders Elm Pedersen.
Immunopharmacol Immunotoxicol, 2014 Feb 22; 36(2). PMID: 24555495
HPV Positive Head and Neck Cancers: Molecular Pathogenesis and Evolving Treatment Strategies.
Rüveyda Dok, Sandra Nuyts.
Cancers (Basel), 2016 Apr 05; 8(4). PMID: 27043631    Free PMC article.
Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck.
Matthew A Ginos, Grier P Page, +6 authors, Patrick M Gaffney.
Cancer Res, 2004 Jan 20; 64(1). PMID: 14729608
Highly Cited.
Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies.
P Vici, L Pizzuti, +20 authors, A Venuti.
Expert Rev Vaccines, 2016 Apr 12; 15(10). PMID: 27063030    Free PMC article.
Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin.
Michael A Curran, Theresa L Geiger, +5 authors, James P Allison.
J Exp Med, 2013 Apr 03; 210(4). PMID: 23547098    Free PMC article.
Highly Cited.
Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients.
Angelica Loskog, Aglaia Maleka, +9 authors, Gustav Ullenhag.
Br J Cancer, 2016 Apr 01; 114(8). PMID: 27031851    Free PMC article.
Development of HPV16,18,31,45 E5 and E7 peptides-based vaccines predicted by immunoinformatics tools.
Ali Namvar, Heidar Ali Panahi, Elnaz Agi, Azam Bolhassani.
Biotechnol Lett, 2020 Jan 10; 42(3). PMID: 31915962    Free PMC article.
Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV+ oral cancer.
Stephanie Dorta-Estremera, Venkatesh L Hegde, +7 authors, K Jagannadha Sastry.
J Immunother Cancer, 2019 Sep 20; 7(1). PMID: 31533840    Free PMC article.
The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer.
Takeo Shibata, Benjamin J Lieblong, Toshiyuki Sasagawa, Mayumi Nakagawa.
Cancer Treat Rev, 2019 Jul 16; 78. PMID: 31302573    Free PMC article.
Cervical Cancer: Emerging Immune Landscape and Treatment.
Luopei Guo, Keqin Hua.
Onco Targets Ther, 2020 Sep 05; 13. PMID: 32884290    Free PMC article.
Human Papillomavirus Vaccines: An Updated Review.
Liqin Cheng, Yan Wang, Juan Du.
Vaccines (Basel), 2020 Jul 28; 8(3). PMID: 32708759    Free PMC article.
Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy.
Muhammad Khan, Zhihong Zhao, +2 authors, Guixiang Liao.
Front Immunol, 2020 Dec 18; 11. PMID: 33329567    Free PMC article.
Novel Antigenic Targets of HPV Therapeutic Vaccines.
Ditte Rahbæk Boilesen, Karen Nørgaard Nielsen, Peter Johannes Holst.
Vaccines (Basel), 2021 Nov 28; 9(11). PMID: 34835193    Free PMC article.
Head and Neck Squamous Cell Carcinoma: Risk Factors, Molecular Alterations, Immunology and Peptide Vaccines.
Zhe Sun, Xiaodong Sun, +2 authors, Yihua Wu.
Int J Pept Res Ther, 2021 Dec 15; 28(1). PMID: 34903958    Free PMC article.
Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer.
Supitcha Kamolratanakul, Punnee Pitisuttithum.
Vaccines (Basel), 2021 Dec 29; 9(12). PMID: 34960159    Free PMC article.
Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier.
Somayeh Vafaei, Angelina O Zekiy, +4 authors, Majid Zamani.
Cancer Cell Int, 2022 Jan 05; 22(1). PMID: 34980128    Free PMC article.